The US Food and Drug Administration (FDA) has allowed marketing of the Xlumena, Inc's Axios Stent and Delivery System for treating pseudocysts (fluid and tissue filled cavities) that form in the ...

TORONTO--(Marketwire - March 12, 2012) - Axios Mobile Assets Corp. (CNSX: AXA) is pleased to announce that the Company closed a financing by way of a private placement. The total financing from the ...

MOUNTAIN VIEW, Calif., May 15, 2012 /PRNewswire/ -- Xlumena, Inc. announces the publication of a scientific paper describing the first human study of the AXIOS™ Stent and Delivery System. The article, ...

Boston Scientific Corporation BSX recently agreed to purchase the majority stake in M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd. This latest investment is aimed at broadening Boston ...

The first stent specifically designed to treat pancreatic pseudocysts yesterday was cleared for marketing by the US Food and Drug Administration (FDA). The Axios stent and delivery system from Xlumena ...

MOUNTAIN VIEW, Calif., July 17, 2012 /PRNewswire/ -- Xlumena, Inc. announces that it has received CE Mark approval to market its AXIOS Stent and Delivery System for biliary tract drainage. The device ...

In a bid to extend its footprint in the multibillion-dollar endoscopy equipment market, Boston Scientific Corporation BSX has commercially launched its FDA-cleared Axios stent and electrocautery ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA will allow the marketing of the ...

Xlumena's Axios stent and delivery system--Courtesy of Xlumena The FDA has approved Xlumena's AXIOS stent and delivery system to treat pseudocysts of the pancreas. In its press release announcing the ...